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HIV-1 Nef is a critical determinant of pathogenicity in humans and transgenic (Tg) mice. To gain a better understanding of the
molecular mechanisms by which Nef induces an AIDS-like disease in Tg mice, a mutational analysis of the N-terminal domain, involved
in anchoring Nef to the plasma membrane, was carried out. The pathogenic effects of these Nef mutant alleles were evaluated in Tg mice
by FACS analysis and by histopathological assessment. Mutation of the myristoylation site (G2A) completely abrogated the development
of the AIDS-like organ disease in Tg mice, although partial downregulation of the CD4 cell surface protein and depletion of peripheral
CD4+ T-cells, but not of CD4+CD8+ thymocytes, still occurred. Despite that, the peripheral CD4+ T cells expressing NefG2A show
normal spontaneous proliferation in vivo or after stimulation in vitro, including in an allogenic mixed leukocyte reaction (MLR). Three
other internal deletion mutants of Nef, spanning amino acids 8–17 (NefD8–17), 25–35 (NefD25–35), and 57–66 (NefD57–66), were also
studied. NefD8–17 retained full pathogenic potential, although NefD25–35 and NefD57–66 Tg mice were free of organ disease. However,
NefD25–35 Tg mice exhibited disorganization of thymic architecture and a partial depletion of peripheral CD4+ T cells. These data indicate
that myristoylation and other regions at the N-terminus of Nef (aa 25–35 and 57–66) are involved in mediating severe T-cell phenotypes
and organ disease, although residues 8–17 are dispensable for these Nef functions. In addition, these results indicate that at least some of
the CD4+ T-cell phenotypes can develop independently of the other AIDS-like organ phenotypes. This apparent segregation of different
Nef-mediated phenotypes suggests distinct mechanisms of Nef action in different populations of target cells, and may be relevant to
human AIDS.
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Nef is a multifunctional protein containing several
domains critical for its function in vitro and in vivo (for
reviews, see refs Cullen, 1994; Fackler and Baur, 2002;
Geyer et al., 2001; Harris, 1996; Skowronski et al., 1999;
Trono, 1995). The critical role of Nef in HIV-1 and SIV
pathogenesis has emerged from studies on long-term non-
progressor patients and rhesus monkeys, respectively,04) 273–286
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strated that such individuals or animals did not develop
disease (Deacon et al., 1995; Kestler et al., 1991; Kirchhoff
et al., 1995). Previous in vitro studies with cell lines also
identified other biological effects of Nef: in particular, Nef
was shown to enhance viral infectivity and virus replication
(reviewed in Harris, 1999) and to mediate the down-
regulation of cell surface expression of CD4 (Piguet et al.,
1999; Skowronski et al., 1999), major histocompatibility
complex (MHC) class I (Le Gall et al., 1997), and of CD28
(Swigut et al., 2001). In addition, Nef has been shown to
either induce (Alexander et al., 1997; Baur et al., 1994;
Biggs et al., 1998; Briggs et al., 1997; Du et al., 1995;
Fackler et al., 1999; Luo and Peterlin, 1997; Schrager and
Marsh, 1999; Whetter et al., 1998) or inhibit (Bandres and
Ratner, 1994; Baur et al., 1994; Collette et al., 1996; De and
Marsh, 1994; Greenway et al., 1995; Iafrate et al., 1997;
Luria et al., 1991; Niederman et al., 1992, 1993a) T-cell
activation.
Structurally, Nef consists of a conserved folded C-
terminal core domain of approximately 120 residues that
contains a helix-turn-helix motif (Grzesiek et al., 1996a;
Lee et al., 1996). This is preceded by a N-terminal arm of
about 70 residues with no defined structure that functions
as a membrane anchor (Freund et al., 1994) containing a
myristoylation group at glycine 2 (G2). This arm is
relatively well conserved and several functions have been
reported to be associated with this region of Nef. In
addition, the Nef N-terminal region contains several basic
residues in the first 22 amino acids that help to stabilize
the interaction of Nef with the plasma membrane by
electrostatic interactions with the acidic phospholipids
(Welker et al., 1998). Several residues in this region
together with a highly conserved stretch of glutamic acid
residues (aa 60–71) are also important for CD4 and MHC
class I downregulation. In particular, residues W57 and
L58 at the N-terminal region together with two pairs of
residues at the C-terminus (L164–L165 and D174–D175)
of Nef have been proposed to participate in CD4 down-
regulation (Bresnahan et al., 1998; Greenberg et al., 1998a;
Grzesiek et al., 1996b; Lock et al., 1999; Lu et al., 1998;
Mangasarian et al., 1999). A putative viral protease
cleavage site between W57 and L58 is also present in
this region (Freund et al., 1994; Pandori et al., 1996;
Welker et al., 1996). In addition, the N-terminus of Nef
was found to be associated with a protein complex
containing Lck, the Polycomb group protein Eed, and a
serine kinase (Baur et al., 1997; Witte et al., 2004).
Furthermore, it has been suggested that the distinct
phenotypes induced by Nef in vivo and in vitro may be
dependent on its localization to different cellular compart-
ments (Arold and Baur, 2001; Baur et al., 1994), mediated
at least in part by the myristoylated N-terminal anchor
domain.
We have previously reported that CD4C/HIVMutG
transgenic (Tg) mice expressing the HIV-1NL4-3 Nef inrelevant target cells of the immune system developed a
severe AIDS-like disease leading to early death (Hanna et
al., 1998b). Several phenotypes of this disease are
remarkably similar to those observed in HIV-1-infected
individuals (Hanna et al., 1998a, 1998b). These include
signs of growth retardation, wasting, and pathologies in
several organs, namely kidney (interstitial nephritis, cystic
dilatation and segmental glomerulosclerosis), lung (lym-
phocytis interstitial pneumonitis), and heart (cardiomyo-
cytis, cardiomyolysis), as well as severe immune abnor-
malities (atrophy of all lymphoid organs, CD4+ T-cell
lymphopenia, T and B cell activation, impaired germinal
center formation, production of auto-antibodies, abnormal
DC functions and distribution) (Hanna et al., 1998a,
1998b; Kay et al., 2002; Poudrier et al., 2001, 2003;
Weng et al., 2004).
In order to understand the molecular mechanisms under-
lying HIV-1 Nef-mediated pathological effects in these Tg
mice, we have investigated the contribution of specific N-
terminal region(s) of Nef to its pathogenicity through a
mutational analysis.Results
Generation of CD4C/HIV-Nef Mut Tg mice
To better understand the role of the N-terminal domain of
HIV-1 Nef in the development of an AIDS-like disease in
vivo, we generated Tg mice expressing four independent
Nef mutant alleles, NefG2A, NefD8–17, NefD25–35, and
NefD57–66, for which in vitro data (Goldsmith et al., 1995;
Guy et al., 1987; Welker et al., 1998) as well as results in
SCID-hu mice (Aldrovandi et al., 1998) were already
available. The NefG2A allele is mutated at the myristoylation
site (G2A), although the other mutants harbor deletions of,
respectively, residues 8–17, 25–35, and 57–66 of the N-
terminal domain of Nef, as described previously (Aldro-
vandi et al., 1998). The mutated Nef sequences replaced the
wild-type Nef (Nefwt) in the HIVMutG cassette in which all
the known open reading frames (ORF), except that of Nef,
have been interrupted by mutations (Hanna et al., 1998b).
The mutated HIV-1 sequences were expressed under the
control of the chimeric human CD4 promoter and mouse
CD4 enhancer regulatory elements (CD4C) to generate
CD4C/HIV-NefG2A, CD4C/HIV-NefD8–17, CD4C/HIV-
NefD25–35, and CD4C/HIV-NefD57–66 Tg mice (Fig. 1).
For each transgene, at least two independent founder (F)
lines faithfully expressing the transgene were established
and studied.
Northern blot analysis on RNA from different organs of
mice from each founder revealed the presence of the three
main HIV-1 RNA transcripts, mainly in lymphoid tissues
(thymus, spleen, and lymph nodes [LN]) and to a lesser
extent in kidneys (Fig. 2A) and lungs (data not shown).
Expression was not detected in other organs (heart, brain,
Fig. 1. Structure of the CD4C/HIV-NefMut transgenes. The CD4C/HIV-NefWT, CD4C/HIV-NefG2A, CD4/HIV-NefD8–17, CD4C/HIV-NefD25–35, and CD4C/
HIV-NefD57–66 transgenes were constructed as described in Materials and methods. Symbols: mCD4enh, mouse CD4 enhancer; hCD4 prom, human CD4
promoter; SV40, polyadenylation sequences from SV40; Ex1, CD4 gene exon1; X represents interruption of the ORF of the indicated HIV-1 gene. Restriction
sites: A, AatII, Bs BssHII, S, SstI.
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pattern reflects the specificity of the CD4C promoter, as
previously documented (Hanna et al., 1994, 1998a, 1998b,
2001a). As expected, the level of RNA expression varied
among founder lines, most likely as a result of distinct
integration sites of the transgene. Consistent with these RNA
data, immunoblot analysis with polyclonal anti-Nef anti-
serum revealed expression of NefMut proteins in lymphoid
tissues at different levels in different founder lines (Fig. 2B):
the order was F51033 N F51039 N F55540 for NefG2A; for
NefD8–17, F69426 N F62815; for NefD25–35, F93570 N
F93567 N F93568 (not shown); and for NefD57–66, F75486 N
F62897 N F75482.
Tg mice from founder lines expressing NefMut at
comparable to (F93567, F75482, F62897, F75486,
F93570) or higher (F51039, F55540, F51033) protein levels
than Tg mice expressing Nefwt (CD4C/HIVMutG, founder
F27367) were selected for comparative studies. This was an
important consideration because we had previously found
that both the incidence and progression of the AIDS-like
disease in Tg mice correlated with the level of Nef
expression (Hanna et al., 1998b).
Tg mice expressing Nef D8–17, but not those expressing
Nef G2A, Nef D25–35, and Nef D57–66, develop an AIDS-like
organ disease
Tg mice and their non-Tg littermates from a minimum of
two founder lines of each mutant line were routinely
monitored for clinical signs of disease (hypoactivity, ruffledhair). Interestingly, CD4C/HIV-Nef D8–17 Tg mice exhibited
a mortality rate close to that of Tg mice expressing Nefwt
(Fig. 3), despite their relatively low levels of Nef
expression. These CD4C/HIV-NefD8–17 Tg mice and addi-
tional ones from founder F69431 developed phenotypes
indistinguishable from those of CD4C/HIVMutG (Nefwt) Tg
mice, previously reported (Hanna et al., 1998b): namely,
hypoactivity, weakness, loss of body weight (wasting),
edema, and early death. Further histological evaluation of
these CD4C/HIV-NefD8–17 Tg mice (including those of
founder F69431) at different ages (2, 6, 9, 14 months old)
revealed the presence of typical transgene-specific patho-
logical lesions that have been observed in our previous
studies with Nefwt-expressing Tg mice (Hanna et al., 1998a,
1998b), such as loss of architecture and atrophy of lymphoid
organs, kidney, lung, and heart (Kay et al., 2002) disease
(Fig. 4, Supplementary Materials, Table A).
In contrast to the CD4C/HIV-NefD8–17, the life span of
CD4C/HIV-NefG2A, CD4C/HIV-NefD25–35, and CD4C/
HIV-NefD57–66 Tg mice was comparable to that of non-
Tg mice (Fig. 3), and these Tg mice survived in apparent
good health during the course of this study (16 months). In
addition, the histological lesions observed in Tg mice
expressing Nefwt were absent in the Tg mice of these three
mutants, except for partial abnormality of the lymphoid
tissues, seen most prominently in Tg mice expressing
NefD25–35. This consisted of partial to complete loss of the
corticomedullary junction of the thymus [100% (n = 33)
vs. 5% (n = 19) for Tg vs. non-Tg thymus, Figs. 4K, L].
In the spleen, disorganization of the architecture, often
Fig. 2. Expression of HIV-1 Nef in CD4C/HIV-NefMut Tg mice. Various tissues from different founder (F) lines of each of the CD4C/HIV-NefMut transgene
were analyzed. (A) Northern blot analysis of HIV-1 RNA. Total RNAs were hybridized with 32P-labeled HIV-1-specific probes. Symbols: T, thymus; S, spleen;
Ln, lymph nodes; K, kidney. (B) Western blot analysis of protein extracts from thymuses from 1-month-old Tg and non-Tg littermates using rabbit anti-Nef
antibodies. NefWT represents the CD4C/HIVMutG (F27367) Tg mice used as positive controls.
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dumbbell shaped follicles), was seen in 17% (n = 41) of
Tg spleens compared to only 3% (n = 29) of non-Tg
spleens. In addition, a pale, hypocellular T-cell zone was
observed in LN of 15% (n = 39) Tg versus only 6% (n =
33) non-Tg animals examined. Disorganization of lym-
phoid tissue architecture was seen with lower frequency in
NefG2A and NefD57–66 expressing Tg mice. Typical Tg-
specific lesions in kidney, lung, and heart were absent in
all NefD25–35, NefD57–66, and NefG2A Tg mice examined.
These results indicated that residues 25–35, 57–66, and themyristoylation signal of Nef are required for its full
pathogenicity in Tg mice.
The G2A, D25–35, and D57–66 mutations of Nef attenuate
its capacity to downregulate the CD4 cell surface
expression and to induce CD4+ T-cell depletion
In order to examine in more detail the status of each T-
cell subpopulation [single-positive (SP) CD4+, SP CD8+
and double-positive (DP) CD4+CD8+ cells], a FACS
analysis was carried out on thymocytes (Fig. 5A) and on
Fig. 3. Survival of CD4/HIV-NefMUT Tg mice. Mice were observed for a period of up to 12 months. The cumulative incidence of mortality of CD4C/HIV-
NefG2A, CD4C/HIV-NefD8–17, CD4C/HIV-NefD25–35, CD4C/HIV-NefD57–66 Tg mice, as well as of their non-Tg littermates were plotted as percentage of
surviving mice. NefWT represents the CD4C/HIVMutG (F 27367) Tg mice used as positive controls. The number of animals observed (n) in NefG2A, NefD25–35,
and NefD57–66 Tg lines represent the sum of mice from all founders in these lines.
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5B) of Tg mice at different ages. In addition, B cells and
macrophages were studied.
Tg mice expressing NefG2A, NefD25–35, and NefD57–66
harbored numbers of total thymocytes comparable to those
of non-Tg littermates (Supplementary Materials, Table B).
A modest depletion of SP CD4+ thymocytes was observed
in CD4C/NefG2A Tg mice (Table 1). In peripheral lymphoid
organs, the numbers of LN and spleen cells were reduced in
Tg mice expressing NefG2A and to a lesser extent in mice
expressing NefD25–35, due to a partial depletion of CD4+ T
cells and to a lesser extent of CD8+ T cells (NefG2A) (Table
1). The partial depletion of CD4+ T cells resulted in
diminished CD4/CD8 cell ratios (Fig. 5, and Supplementary
Materials, Table D). Moreover, a partial downregulation
(50–70%) of CD4 surface protein was observed on
thymocytes (Fig. 5A) and T cells from peripheral organs
(Fig. 5B) of CD4C/HIV-NefG2A Tg mice, although the
CD4C/HIV-NefD25–35 Tg mice had a minor (20–25%)
downregulation of CD4, observed mainly in T cells of the
peripheral organs (Table 1) (Fig. 5). This reduced CD4+ T-
cell number and downregulation of CD4 surface expression
was stably maintained during the life span of the animals.
The FACS analysis performed on cells from thymuses and
peripheral organs of CD4C/HIV-NefD57–66 Tg mice showed
no significant differences from non-Tg profiles (Fig. 5,
Table 1, and Supplementary Materials Tables B, C, D).
Moreover, profiles with other cell markers (B220, Mac-1)
studied in the CD4C/HIV-NefG2A CD4C/HIV-NefD25–35
and CD4C/HIV-NefD57–66 Tg mice were comparable to
those of non-Tg littermates.In the CD4C/NefD8–17 Tg mice, total cell numbers in
thymus and in peripheral organs were decreased as compared
to non-Tg animals (Supplementary Materials, Table B). This
was reflected by a depletion of immature DP CD4+CD8+
thymocytes, as well as mature SP CD4+ T cells in the
thymus and peripheral organs (Figs. 5A, B). Also, the CD4
surface protein expression on the DP CD4+CD8+ and SP
CD4+ thymocytes (Fig. 5A, Table 1) and on peripheral
CD4+ T cells (Fig. 5B, Table 1) was severely downregulated
in these NefD8–17-expressing Tg mice, as previously
documented in Tg mice expressing Nefwt (Hanna et al.,
1998b).
A summary of all the FACS data is presented (Table 2).
Together, these results show that N-terminal residue D57–66
is required, although the myristoylation site and other N-
terminus residues of Nef (aa 8–17, aa 25–35) are dispensable
for at least partial CD4 cell surface downregulation and
depletion of CD4+ T cells in an in vivo context, although
attenuation of these phenotypes is observed in Nef G2A- and
NefD25–35-expressing cells.
Cell surface downregulation of CD4 on CD4+ T cells
expressing NefG2A does not impair their capacity to
proliferate in vitro, nor to spontaneously divide in vivo
In contrast to the other Tg lines free of kidney, lung, and
heart disease (NefD25–35, NefD57–66), the CD4C/HIV-NefG2A
Tg mice exhibited lower numbers of SP CD4+ lymphocytes
and significant downregulation of CD4 expression on DP
thymocytes and on SP CD4+ T cells. The functions of these
SP CD4+ T cells were therefore further studied.
Fig. 4. Histopathology observed in CD4C/HIV-NefD8–17 and CD4C/HIV-
NefD25–35 Tg mice. Non-Tg control (A, C, E, G, I, K) and CD4C/HIV-
NefD8–17 (B, D, F, H, J) or CD4C/HIV-NefD25–35 Tg (L) tissues are shown:
thymus (A, B, and K, L), LN (C, D), kidney (E, F), lung (G, H), and heart
(I, J). The CD4/HIV-NefD8–17 Tg mice exhibit the typical pathology
previously observed in CD4C/HIV-NefWt Tg mice. Note the loss of
architecture and hypocellularity of thymus (B) and lymph node (D).
Tubular dilatation, atrophy, with some cystic changes, tubolointersitial
nephritis, and glomerulosclerosis are observed in Tg kidney (F). Lympho-
cytic interstitial pneumonitis is seen in Tg lung (H). Tg heart exhibits
myocytolysis with myocarditis and calcifications (J). The CD4C/HIV-
NefD25–35 Tg mice only show a loss of their thymic architecture (L). Small
letters in A and K identify thymus cortex (c) and medulla (m). Scale bars as
in I and J represent 100 Am, in all other panels, 250 Am.
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Nefwt had defects of CD4+ T-cell-dependent functions, in
particular an impairment in GC formation and a failure ofimmunoglobulin isotype class switching (Poudrier et al.,
2001). To examine whether CD4 downregulation alone, in
the absence of other severe AIDS-like phenotypes, would
affect T helper cell functions, we assessed the formation of
T-cell-dependent GC in CD4C/NefG2A Tg mice (F55540)
after immunization with ovalbumin (OVA). In response to
OVA, the CD4C/HIV-NefG2ATg mice exhibited normal GC
formation in both LN and spleen (Poudrier et al., 2001) and
normal immunoglobulin isotype class switching, in contrast
to Tg mice expressing Nefwt (data not shown).
Additional assays were carried out to study the impact of
CD4 downregulation on CD4+ T-cell function. We pre-
viously observed a significant decrease of cell division
potential following in vitro stimulation of Tg CD4+ T cells
expressing Nefwt (CD4C/HIVMutA, Hanna et al., 2001b, and
CD4C/HIVMutG, Weng et al., 2004), as compared to those
from control non-Tg mice, using the CFSE labeling
technique (Lyons and Parish, 1994). Using a similar
approach, we found that following stimulation with anti-
CD3 + anti-CD28 mAbs (Fig. 6A), anti-CD3 + IL-2, or with
PMA/Iono (Fig. 6B), purified CD4+ T cells from CD4C/
HIV-NefG2A Tg mice proliferated to the same extent as
those from non-Tg controls.
We next measured the capacity of LN CD4+ T cells from
CD4C/HIV-NefG2A Tg mice to respond in an allogenic
mixed leukocyte response (MLR). In this assay, T cells from
CD4C/HIV-NefMutG (Nefwt) Tg mice showed a decreased
response, at all APC/T-cell ratios tested (Weng et al., 2004)
(Fig. 6C). Irradiated total splenocytes from BALB/c (H-2d)
mice were used as stimulators to induce proliferation of
purified allogenic CD4+ T cells from CD4C/HIV-NefG2ATg
and non-Tg C3H (H-2k) mice. The proliferation of CD4+ T
cells expressing NefG2A was not significantly lower than
that of control non-Tg cells, in contrast to the lower
response observed in Nefwt-expressing CD4+ T cells (Fig.
6C). Similar MLR responses were also observed with total T
cells or with high-density CD4+ T cells from non-Tg and
NefG2A-expressing Tg mice (data not shown).
Division of NefG2A-expressing CD4+ T-cells in vivo was
next assessed using BrdU labeling. This analysis revealed
that the numbers of BrdU-positive CD4+ Tcells from CD4C/
HIV-NefG2A Tg mice were comparable to those of non-Tg
controls (Figs. 7A, B). These results were in contrast to the
higher percentage of BrdU-positive CD4+ Tcells observed in
Tg mice expressing Nefwt (Figs. 7A, B) (Weng et al., 2004).
Together, these results suggest that mechanisms other than
CD4 downregulation alone are responsible for the prolifer-
ation abnormalities of CD4+ T cells and the impaired CD4+
T-cell-dependent functions observed in Tg mice expressing
Nefwt.Discussion
In the present study, the in vivo pathogenicity of the
N-terminal region of Nef was investigated using a
Z. Hanna et al. / Virology 327 (2004) 273–286 279mutational approach. Tg mice expressing Nef G2A
remained healthy and did not develop an AIDS-like
organ disease, although a partial downregulation of the
CD4 cell surface protein on both thymocytes and
peripheral T cells and a partial depletion of SP CD4+ T
cells was documented in these Tg mice. The myristoy-
lation site of Nef is required for its association with the
plasma membrane and cytoskeletal elements (Fackler et
al., 1997; Niederman et al., 1993b), as well as for most
known functions of Nef. However, contradictory results
have been reported for the effects of mutation of the
myristoylation site of Nef on CD4 downregulation in
vitro, some investigators observing a partial downregula-
tion (Hua et al., 1997; Iafrate et al., 1997), although
others did not (Wang et al., 2000; Wiskerchen and
Cheng-Mayer, 1996). Our findings indicate that myristoy-
lation of Nef is not an absolute prerequisite for at least
partial CD4 downregulation and partial depletion of
primary CD4+ T cells by Nef in mice. The same Nef
mutant used in other biological assays gave results
consistent with our data: it was not fully pathogenic in
SCID-hu mice (Aldrovandi et al., 1998) and induced only
partial CD4 downregulation and minimal loss of CD4+
thymocytes derived in fetal organ culture from Nef-
transduced human CD34+ precursor cells (Stove et al.,
2003). Interestingly, the consequences of the myristoyla-
tion mutation of Nef were more apparent in non-T-cells
than in CD4+ T cells (see below), suggesting a less
stringent requirement for cellular factor(s) at or near the
cell membrane in CD4+ T cells.
Tg mice expressing the NefD25–35 and NefD57–66 alleles
also failed to develop the typical AIDS-like disease
associated with expression of Nefwt in Tg mice, indicating
a critical role of domains within these deleted 25–35 and
57–66 residues in the induction of a multi-organ disease in
Tg mice. Although a partial depletion of CD4+ T cells in
peripheral lymphoid organs and a partial disruption of the
thymic corticomedullary junction were observed in CD4C/
NefD25–35 Tg mice, no depletion of thymocytes occurred in
either CD4C/NefD25–35 or CD4C/NefD57–66 Tg mice,
indicating a much reduced pathogenicity of these mutants.
The finding that the NefD57–66 mutant had lost the capacity
to down modulate cell surface CD4 expression was
expected because the 57–66 aa deleted segment lacked
the glutamic acid cluster and residues W57 and L58
previously shown to interact with the cytoplasmic tail of
CD4 and known to be important for CD4 downregulation
(Grzesiek et al., 1996b; Hua et al., 1997; Lu et al., 1998;
Mangasarian et al., 1999). This is in agreement with
Goldsmith et al. (1995) who found that an overlapping
deletion (aa 60–71) abrogated CD4 downregulation in
vitro. However, our data intriguingly contrast with previous
work showing that the same Nef mutants (NefD25–35,
NefD57–66) were as effective as Nefwt in depleting
thymocytes of HIV-1-infected SCID-hu mice (Aldrovandi
et al., 1998). In a previous study, we have alsodemonstrated that another Nef mutant (A72xxA75) was
nonpathogenic in Tg mice (Hanna et al., 2001b), although
it was reported to be pathogenic in SCID-hu mice
(Aldrovandi et al., 1998; Stoddart et al., 2003). The
reasons for these discordant results are not obvious, but
may be related to different mechanisms of CD4+ T-cell
depletion in the two models. Thus, apparently, each model
scores different functions of Nef.
Among the four mutated Nef alleles studied here, only
mutant NefD8–17 expressed in Tg mice led to the develop-
ment of a multi-organ AIDS-like disease very similar to
that induced by Nefwt despite a relatively low expression
level. Deletion of residues 8–17 appears to relieve an
inhibition on the Nef molecule, possibly bringing the
folded core domain closer to the plasma membrane and
allowing it to interact more efficiently with cellular
factor(s) at the plasma membrane. This region (aa 8–17)
has been postulated to contain a nuclear targeting sequence
that is important for the nuclear localization of Nef (Murti
et al., 1993). Additionally, these sequences were found to
be required for single-cycle infectivity (Welker et al.,
1998), but not for viral infectivity (Goldsmith et al., 1995),
especially in PBMC (Welker et al., 1998), nor for Nef
incorporation into virions (Welker et al., 1998). Finally, the
same mutation, in agreement with our results, did not
abrogate the pathogenicity of Nef in the SCID-hu model
(Aldrovandi et al., 1998).
Together, this structure-function analysis of Nef high-
lighted the role of N-terminal sequences for proper Nef
functions in vivo and importantly, their relative contribution
to induction of each of the distinct phenotypes observed in
this Tg model. In fact, the present analysis has allowed
segregation of different functions of Nef and of different
phenotypes in these Tg mice.
First, we demonstrate here that CD4 downregulation and
depletion of CD4+ T cells do not always correlate. The CD4
downregulation observed in DP thymocytes of CD4C/HIV-
NefG2A Tg mice was not accompanied by depletion of these
DP cells. A similar result was obtained with the same
NefG2A mutant assayed in CD34+ human precursor cells
differentiating in vitro in fetal organ culture (Stove et al.,
2003). However, our results differ from those of Stoddart et
al. (2003) who found a close correlation between the ability
of Nef mutants to downregulate CD4 and their pathoge-
nicity in vivo in SCID-hu mice. Other variable, such as viral
replication and infectivity, which are not scored in a Tg
model, or different mechanism of CD4 downregulation
induced by Nefwt and NefMut, may explain these apparent
contradictory results.
Second, the present study raises the possibility that CD4
downregulation may not be the only cause of the in vitro
decreased and the in vivo increased proliferation of Tg SP
CD4+ T cells expressing Nef. We have recently reported
that CD4+ T cells from Tg mice expressing the Nefwt
exhibit a severe reduction in their capacity to divide in
vitro in response to anti-CD3 and anti-CD28 stimulation
Z. Hanna et al. / Virology 327 (2004) 273–286280
Table 1
Cell surface marker analysis in CD4C/HIV-NefMut Tg mice
Mouse linea Cell number (106) in different subpopulations Mean fluorescence (%)c
Thymus Spleen Thymus Spleen
CD4+CD8+ CD4+CD8 CD4+ CD8+ B220 SP CD4+ SP CD8+ CD4+ CD8+
Non-Tgb 96.4 F 12.6 8.6 F 1.0 22.4 F 5.1 10.7 F 3.3 54.2 F 5.4 100 100 100 100
CD4C/
HIV-NefWt
14.7 F 2.4d 1.1 F 0.5d 10.1 F 1.1d 4.9 F 0.9d 36.1 F 4.9 39.3 F 9.3d 88.3 F 9.1 40.2 F 9.4d 95.6 F 7.7
CD4C/HIV-Nef G2A
F51033 83.4 F 27.1 3.3 F 0.3d 11.5 F 3.7d 6.5 F 3.7 53.1 F 12.7 53.5 F 10.8d 93.3 F 8.1 41.9 F 2.0d 86.9 F 6.1
F55540 90.5 F 19.8 3.7 F 0.9d 9.4 F 0.9d 5.8 F 1.1d 60.1 F 5.3 48.2 F 11.2d 96.1 F 12.3 47.5 F 7.9d 90.3 F 5.9
F51039 87.9 F 3.7 4.3 F 2.0 13.2 F 4.7 5.9 F 1.3 58.1 F 7.7 82.5 F 9.7 92.3 F 9.0 97.4 F 5.4 95.4 F 3.1
CD4C/HIV-Nef D8–17
F62815 28.9 F 20.0d 1.9 F 0.8d 3.9 F 3.1d 2.1 F 2.8d 28.6 F 7.4 40.6 F 25.2d 91.1 F 6.6 44.6 F 9.1d 97.4 F 12.3
F69426 25.6 F 16.4d 2.1 F 0.6d 13.8 F 2.4 7.5 F 1.6 48.5 F 3.3 85.3 F 20.1 98.3 F 9.3 98.1 F 8.4 91.3 F 15.3
CD4C/HIV-Nef D25–35
F93567 69.7 F 15.0 6.0 F 1.5 11.2 F 1.9d 7.6 F 1.8 69.3 F 17.4 88.8 F 6.0 93.4 F 11.2 78.4 F 5.1 90.8 F 4.0
F93568 84.1 F 19.3 7.1 F 3.1 11.3 F 2.0d 8.3 F 2.2 71.9 F 19.1 91.3 F 11.1 98.1 F 10.1 77.1 F 4.6 91.0 F 4.9
F93570 94.3 F 21.6 9.6 F 1.4 11.0 F 2.3d 8.8 F 2.6 76.6 F 18.8 87.4 F 6.4 96.3 F 13.1 75.7 F 4.3 89.0 F 4.1
CD4C/HIV-Nef D57–66
F75482 92.6 F 21.9 7.3 F 2.7 17.6 F 4.6 7.3 F 1.9 61.6 F 22.4 97.3 F 7.2 98.0 F 3.2 98.7 F 2.3 99.5 F 6.3
F75486 94.5 F 27.9 7.8 F 2.9 20.9 F 6.2 8.7 F 3.3 72.7 F 30.9 97.3 F 15.5 97.1 F 5.1 99.1 F 1.3 103.6 F 8.9
F62897 113.3 F 21.7 10.3 F 2.3 16.9 F 4.1 7.1 F 1.1 63.1 F 21.1 98.9 F 15.0 98.3 F 7.2 97.9 F 1.3 99.4 F 6.1
a FACS analysis was performed on at least nine mice (3 to 9 months old) for each Tg line. The positive control CD4C/HIV-NefWt Tg mice were 3 to 6 months
old.
b The non-Tg control values were obtained by pooling the results of all non-Tg littermates from different lines.
c The mean fluorescence for CD4 and CD8 were obtained by calculating the ratio of CD4 or CD8 staining in Tg relative to that of non-Tg tissues (100%)
Mean values were then calculated with the values for each line.
d P b 0.05 by using Student’s t test.
Z. Hanna et al. / Virology 327 (2004) 273–286 281(Hanna et al., 2001b; Weng et al., 2004). Additionally,
these CD4+ T cells expressed low levels of CD40 ligand,
and accordingly, impairment of GC and FDC network
formations as well as immunoglobulin isotype class
switching are observed in these animals (Poudrier et al.,
2001). The partial reduction of CD4 cell surface expression
in NefG2A Tg mice failed to significantly affect these CD4+
T-cell functions (Figs. 6 and 7; Poudrier et al., 2001).
However, because the degree of CD4 downregulation in
NefG2A-expressing Tg mice is not as pronounced as in
NefWT-expressing Tg mice, this leaves open a possible
partial role of CD4 downregulation in the above mentioned
phenomena.
Finally, the analysis of these Nef mutants has
demonstrated a clear segregation of T-cell phenotypes
from the other organ phenotypes [lymphocytic interstitial
pneumonitis, wasting, kidney (interstitial nephritis, cystic
dilatation, segmental glomerulosclerosis), and cardiac
disease] induced in these Tg mice by Nefwt (Hanna etFig. 5. Phenotypic analysis of thymic and peripheral T lymphocytes from CD4C/HIV-NefMut Tg Mice. Thymus (A) and mesenteric LN (B) cells from
representative CD4C/HIV-NefG2A (F57033), CD4C/HIV-NefD8–17 (F62815), CD4C/HIV-NefD25–35 (F93567), CD4C/HIV-NefD57–66 (F62897), and CD4C
HIV-NefWT (F27367) Tg mice and from a non-Tg littermate were analyzed by flow cytometry for the expression of CD4, CD8, TcRah, and Thy1.2. The
percentage of cells found in each quadrant is indicated. The dotted lines were drawn to facilitate the visualization of the CD4 downregulation..al., 1998a, 1998b; Kay et al., 2002). None of the Tg mice
expressing NefG2A, NefD25–35, and NefD57–66 developed
these organ phenotypes. However, some of them still
demonstrated some abnormalities of lymphoid tissue
architecture and CD4+ T-cell function. Therefore, these
results suggest that the CD4+ T-cell depletion or CD4
downregulation and the other organ diseases represent
distinct and independent entities, most likely reflecting the
action of Nef in distinct cell populations. These sub-
populations possibly include macrophages and DC, which
have been shown to express Nef with these regulatory
sequences (Hanna et al., 1994, 1998a, 2001a). Consistent
with this interpretation, we recently reported that the
multi-organ disease of CD4C/HIV-Nefwt Tg mice still
develops when these Tg mice are bred on CD4 gene-
deficient background, that is, in absence of CD4+ T cells
(Weng et al., 2004).
In conclusion, this mutational analysis of Nef has
revealed that Nef-induced downregulation of CD4 cell/
Table 2
Summary of Nef induced phenotypes in CD4C/HIV-NefMut Tg mice
Nef allele Downregulation of CD4 Depletion of T cells Organ disease
DP SP Peripheral Thymus
CD4 CD8 DP CD4 SP CD8 SP
WT ++++ ++++ ++++ +++ ++++ ++++ +++ +++
NefG2A +++ +++ +++ ++  ++  
NefD8–17 ++++ +++ ++++ +++ ++++ ++++ +++ +++
NefD25–35   ++ +/    
NefD57–66    +/    
Z. Hanna et al. / Virology 327 (2004) 273–286282surface expression is not necessarily associated with loss
of CD4+ T-cell functions. It also showed that the
phenotypes observed in CD4+ T cells (low number,Fig. 6. NefG2A, in contrast to NefWT, has little effect on the proliferation of peri
profiles of CFSE-labeled CD4+ T cells. Fresh single-cell suspensions were prepare
presence of both anti-CD3 and anti-CD28 mAb, the cells were harvested and stain
live (PI-negative) CD4+ T cells. M1 represents undivided cells and M2 to M6
representative out of four experiments involving non-Tg, NefG2A, and NefWT CD
division. (B) Histograms representing the percentages (mean F SEM) of CD4+ T
CD3 + anti-CD28, anti CD3 + IL-2, and PMA + Iono. The results are from eigh
Statistical significance of pooled data from four experiments was determined by t
from peripheral LN of CD4C/HIV-NefG2A, CD4C/HIV-NefWT, and non-Tg litter
mice at different ratios for 48 h. Proliferation was evaluated by 3H-thymidine incor
cells cultured in medium alone were subtracted from those obtained after stimulat
experiment at cell ratio 1:1 are shown. Data pooled from four experiments with no
Tg mice. Data were analyzed using the Student’s t test. *P = 0.02.CD4 downregulation) segregate independently of the
other AIDS-like organ phenotypes in this Tg mouse
model. Some of these features may be relevant to humanpheral CD4+ T cells in response to in vitro stimulations. (A) Fluorescence
d from peripheral LNs and labeled with CFSE. After 3 days of culture in the
ed with CD4-PE mAb. Dead cells were excluded from analysis by gating on
represent cells that divided one to five times. The results are from one
4+ T cells. Note that mice expressing NefWT exhibit significant delay in cell
cells in indicated generations upon 3 days of in vitro stimulation with anti-
t non-Tg, eight CD4C-HIV-NefG2A, and four CD4C-HIV-NefWT Tg mice.
he Student’s t test. **P b 0.01. (C) Allogenic MLR. Purified CD4+ T cells
mates were cocultured with allogenic irradiated spleen cells from BALB/c
poration for the final 18 h. For each group, the values (cpm) obtained from T
ion. Non-Tg values were adjusted to 1.0 for each experiment. Data from an
n-Tg (n = 10), CD4C/HIV-NefWT (n = 9), and CD4C/HIV-NefG2A (n = 8)
Fig. 7. NefG2A, in contrast to NefWT, has little impact on the proliferation of
peripheral CD4+ T cells in vivo. (A) Tg mice from CD4C/HIVMutG
(NefWT), CD4C/HIV-NefG2A, and their non-Tg littermates were given
BrdU in drinking water for 14 days. After this labeling period, LN CD4+ T
cells were purified by negative selection, stained for surface CD4 followed
by intracellular staining with anti-BrdU FITC mAb, and analyzed by FACS.
Data represent one out of three experiments. The percentages of BrdU-
positive CD4+ T cells are indicated. (B) Histogram representing quantitation
of BrdU-positive CD4+ T cells in S phase. Data similar to those shown in
panel A were pooled from eight non-Tg mice, seven CD4C-HIV-NefG2A,
and seven CD4C-HIV-NefWT Tg mice in three distinct experiments.
Statistical analysis was performed using the Student’s t test.
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expressing cells are often present at birth, as in these
Tg mice.Materials and methods
Mice
The CD4C/HIVMuG Tg mice have been described (Hanna
et al., 1998b). These Tg mice harbor a complete HIV-1NL4-3
genome in which all the known open reading frames (ORF),
except that of Nef, have been interrupted bymutations. These
Tg mice express only the wild-type Nef (Nefwt). The CD4C/
HIV-NefG2A transgene was constructed by mutating the
glycine (G) residue at position two of Nef in the CD4C/
HIVMutG transgene to alanine (NefG2A). The CD4C/HIV-
NefD8–17, CD4C/HIV-NefD25–35, and CD4C/HIV-NefD57–66
transgenes were constructed by deleting codons 8–17, 25–35,
and 57–66, respectively, of the N-terminal arm of Nef (seeFig. 1). These mutations were produced by PCR site-directed
mutagenesis, on a SacI–BamHIHIV-1 fragment subcloned in
pBS KS vector, using primer #512 (5-CACTTGCCAGC-
CATCTTATAGC-3) containing C to G mutation at nt 8791,
to produce NefG2A mutation and primers #626 (5V-
CTCAGCTCGTCTCATTCTTTCTAGACCACTTGCC-3),
#1023 (5V-ATGTTTTTCTAGGTCCTCAGCTCGTCT-
CATTCTTTC-3), and #627 (5V-AGGTGTGACTGGAA-
AACCGGCACAAGCAGCATTGTTAGC-3) to produce
NefD8–17, NefD25–35, and NefD57–66 mutants, respectively
(Aldrovandi et al., 1998; Welker et al., 1998). Mutations
were then confirmed by sequencing and each of the SacI–
BamHI fragment harboring the mutation was incorporated
into the CD4C/HIVMutG DNA backbone, thus replacing
Nefwt. Each transgene was purified and inoculated into 1-
day-old (C57BL/6  C3H) F2 embryos to generate Tg
mice, as described (Hanna et al., 1998a, 1998b). A
minimum of two independent founder (F) Tg mice
faithfully expressing each transgene were generated. Tg
lines were established by breeding as heterozygote for the
transgene on the C3H/He background.
Transgene expression
Transgene expression was measured by Northern and
Western blot analysis, as previously described (Hanna et al.,
1998a, 1998b, 2001b). The rabbit anti-Nef antibody used
was prepared using GST-Nef fused protein (1:2000).
Production of anti-Nef antibodies was described previously
(Hanna et al., 2001b). The monoclonal anti-Nef AE6
antibody (Greenway et al., 1994) was also used with similar
results (data not shown).
Histological analysis
Histological assessment on lymphoid and nonlymphoid
organs was carried out essentially as previously described
(Hanna et al., 1998a, 1998b).
Flow cytometry
Flow cytometry was performed on a FACScan and
FACS Calibur (Becton BD Dickinson, San Jose, CA)
using antibodies specific for various cell surface markers:
CD4, CD8, TcRah, and Thy1.2 for T cells and B220,
Mac-1 for B cells and macrophages, respectively, as
described previously (Hanna et al., 1998a, 1998b, 2001b).
CellQuest Software (Becton BD Dickinson) was used for
analysis.
Purification of CD4+ T cells
CD4+ T cells were purified by cell sorting, by negative
selection, as previously described (Weng et al., 2004).
Lymph node (LN) cells were resuspended for 20 min in
blocking buffer (PBS, 20% fetal bovine serum [FBSI],
Z. Hanna et al. / Virology 327 (2004) 273–286284Gibco/BRL, Life Technologies, without sodium azide).
Staining was performed with PE-coupled anti-MHC II
(M5–114), anti-CD8 (53–6.72), anti-B220 (RA36B2), and
anti-TcRgy mAb (Cedarlane) on ice for 40 min. CD4+ T
cells were sorted by gating on the PE-negative population.
The purity of CD4+ TCRah+ cells obtained by this
procedure was 95–98%, as confirmed by flow cytometry.
Generation of an in vitro allogenic mixed leukocyte reaction
The procedure to generate in vitro MLRs has been
described previously (Weng et al., 2004). Splenocytes from
sex-matched BALB/c mice of 6–12 weeks of age were
irradiated (2500 rads) and used as stimulating APCs in the
MLR. Cells were cocultured in round bottom 96-well plates,
in IMDM (Gibco-BRL) supplemented with 5% FBS, l-
glutamine, 2-ME, and antibiotics. CD4+ T cells were
cultured at a density of 1.5–2  105 cells/well and APCs
were added at different ratios. For control, ConA+ and IL-2
were added at a final concentration of 2.5 Ag/ml and of 50
U/ml, respectively. Proliferation was assessed by the
incorporation of 3H-thymidine (Amersham) for the final
18 h of a 48-h culture period.
Immunization
Mice (8–10 weeks of age) were immunized with alum-
precipitated ovalbumin (OVA) (Sigma), as described pre-
viously (Poudrier et al., 2001).
CFSE fluorescent dye cell labeling
CFSE (5- and 6-carboxyfluorescein diacetate succini-
midyl ester, Molecular Probes Inc; Eugene, OR) labeling
was performed as previously described (Hanna et al., 2001b;
Weng et al., 2004), on total LN cells or on negatively sorted
CD4+ T cells.
Measurement of in vivo DNA synthesis by BrdU
incorporation
This procedure has been described previously (Weng et
al., 2004).
Statistics
Statistical analysis (ANOVA, Sigmastat, and Student’s t
test) was performed as previously described (Hanna et al.,
2001b; Weng et al., 2004).Acknowledgments
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